[go: up one dir, main page]

CA2366895A1 - Polymeres immunoregulateurs - Google Patents

Polymeres immunoregulateurs Download PDF

Info

Publication number
CA2366895A1
CA2366895A1 CA002366895A CA2366895A CA2366895A1 CA 2366895 A1 CA2366895 A1 CA 2366895A1 CA 002366895 A CA002366895 A CA 002366895A CA 2366895 A CA2366895 A CA 2366895A CA 2366895 A1 CA2366895 A1 CA 2366895A1
Authority
CA
Canada
Prior art keywords
polymer
repeating
repeating charge
positively charged
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002366895A
Other languages
English (en)
Inventor
Arthur O. Tzianabos
Dennis L. Kasper
Andrew B. Onderdonk
Ying Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2366895A1 publication Critical patent/CA2366895A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Surgery (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des techniques et des produits permettant d'induire une sécrétion IL-2, une sécrétion IL-10, d'activer les lymphocytes T, de supprimer la réponse de l'anticorps IgG à un antigène spécifique, de favoriser la survie des allogreffes, de réduire la formation d'adhérences postchirurgicales, et de protéger contre la formation d'abcès associée à la chirurgie, aux traumatismes ou aux maladies qui prédisposent à la formation d'abcès chez le patient. On réalise les techniques de cette invention en utilisant un immunorégulateur qui est un polymère possédant au moins deux motifs de charge répétés séparés au moins par une certaine distance minimum.
CA002366895A 1999-04-02 2000-03-31 Polymeres immunoregulateurs Abandoned CA2366895A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12758499P 1999-04-02 1999-04-02
US60/127,584 1999-04-02
US16245799P 1999-10-29 1999-10-29
US60/162,457 1999-10-29
PCT/US2000/008586 WO2000059515A2 (fr) 1999-04-02 2000-03-31 Polymeres immunoregulateurs

Publications (1)

Publication Number Publication Date
CA2366895A1 true CA2366895A1 (fr) 2000-10-12

Family

ID=26825761

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002366895A Abandoned CA2366895A1 (fr) 1999-04-02 2000-03-31 Polymeres immunoregulateurs

Country Status (8)

Country Link
EP (1) EP1169045A2 (fr)
JP (2) JP2002541113A (fr)
CN (1) CN1362880A (fr)
AU (1) AU781950B2 (fr)
BR (1) BR0009531A (fr)
CA (1) CA2366895A1 (fr)
MX (1) MXPA01009930A (fr)
WO (1) WO2000059515A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
WO2003066053A1 (fr) * 2002-02-07 2003-08-14 Rutgers, The State University Polymeres antibiotiques
EP1494687A2 (fr) 2002-03-08 2005-01-12 Eli Lilly And Company Antigenes polymeres immunomodulateurs pour le traitement de maladies inflammatoires
AU2004227852B2 (en) * 2003-03-31 2010-01-14 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
WO2007092451A2 (fr) 2006-02-06 2007-08-16 The Brigham And Women's Hospital, Inc. Polysaccharides zwitterioniques pour favoriser la maturation du système immunitaire et la santé
EP2217250A4 (fr) * 2007-11-09 2011-01-05 California Inst Of Techn Composés immunorégulateurs et compositions et procédés apparentés
US8580278B2 (en) 2009-06-03 2013-11-12 Trustees Of Dartmouth College Nutraceutical composition and methods for preventing or treating multiple sclerosis
US20110251156A1 (en) 2010-04-07 2011-10-13 Yue Shen Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
CA2911826C (fr) 2013-05-10 2022-08-23 California Institute Of Technology Prevention et traitement probiotiques du cancer du colon
JP6206916B2 (ja) * 2013-11-15 2017-10-04 国立研究開発法人物質・材料研究機構 細胞間情報伝達分子産生信号誘発機能高分子及びその合成方法
WO2016201342A1 (fr) 2015-06-10 2016-12-15 California Institute Of Technology Traitement du sepsis, compositions, méthodes et systèmes associés
CN108135167B (zh) 2015-08-19 2021-07-09 哈佛学院院长及董事 脂化psa组合物和方法
WO2018014012A1 (fr) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Compositions de glycolipide et procédés d'utilisation
CN110100001B (zh) 2016-10-27 2024-03-01 长庚医疗财团法人林口长庚纪念医院 评估磺胺甲基异噁唑及/或甲氧苄氨嘧啶引发药物过敏反应风险的方法
PE20200303A1 (es) 2017-05-24 2020-02-06 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer
WO2019189767A1 (fr) * 2018-03-29 2019-10-03 三菱電機ビルテクノサービス株式会社 Dispositif de chauffage, procédé de chauffage, et procédé de récupération de réfrigérant
WO2019189769A1 (fr) * 2018-03-30 2019-10-03 味の素株式会社 Composition pour croissance cellulaire

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3704389A1 (de) * 1987-02-12 1988-08-25 Blutspendedienst Dt Rote Kreuz Verfahren zur herstellung von lymphokinen durch induktion lymphoider zellen
US5700787A (en) * 1994-09-02 1997-12-23 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD

Also Published As

Publication number Publication date
AU781950B2 (en) 2005-06-23
WO2000059515A9 (fr) 2002-08-29
BR0009531A (pt) 2001-12-26
EP1169045A2 (fr) 2002-01-09
CN1362880A (zh) 2002-08-07
AU4056300A (en) 2000-10-23
JP2002541113A (ja) 2002-12-03
JP2011121986A (ja) 2011-06-23
MXPA01009930A (es) 2003-07-14
WO2000059515A3 (fr) 2001-01-11
WO2000059515A2 (fr) 2000-10-12

Similar Documents

Publication Publication Date Title
JP2011121986A (ja) 免疫調節ポリマー
US7083777B1 (en) Immunomodulating polymers
EP0778780B1 (fr) Immunomodulateur polysaccharidique capsulaire
US5679654A (en) Capsular polysaccharide immunomodulator
Murphy et al. New strategies for preventing graft-versus-host disease
US20100310470A1 (en) Immunomodulatory polymeric antigens for treating inflammatory pathologies
Prakken et al. Heat shock protein 60 and adjuvant arthritis: a model for T cell regulation in human arthritis
JP2010265293A (ja) 免疫無防備状態の個体群に用いる糖コンジュゲートワクチン
EP1459757A1 (fr) Polymères immunomodulateurs
EP0681479B1 (fr) Composition immunotherapeutique
US8129518B2 (en) Synthetic polysaccharide antigens for immunological intervention in disease
US20090176696A1 (en) Methods And Compositions For Modulating An Immune Response
AU2005201963B2 (en) Immunomodulating polymers
AU702325C (en) Capsular polysaccharide immunomodulator
AU738824B2 (en) Capsular polysaccharide immunomodulator
EP0842666A2 (fr) Utilisation combinée des peptides synthétiques contre l'endotoxine et des anticorps contre l'endotoxine pour la prophylaxie et le traitement de l'endotoxicose et du choc septique
AU2011203013A1 (en) Synthetic polysaccharide antigens for immunological intervention in disease

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130402